Watson Bio [300142] said in an interactive platform today in response to investors' questions that the company's new coronavirus variant mRNA vaccine (S protein chimera), which has entered the Phase III clinical research stage, has carried out clinical trial plans covering the main currently popular strains. The antigen integrates all mutation sites of the Alpha variant and key mutation sites of the Beta variant, which has covered 7 mutation sites of the Omicron variant. In addition, the bivalent vaccine RQ3025 jointly developed by the company and Blue Que Biotechnology uses two pieces of mRNA design to encode a chimeric S protein antigen. Preclinical studies have shown that it can produce effective neutralizing antibodies against the main strains currently circulating. The company is currently advancing preparations for clinical application of this vaccine candidate. The company
stated that the new coronavirus mRNA vaccine developed by the company in cooperation with Aibo was developed against the original strain. The COVID-19 mRNA vaccine jointly developed by the company and Blue Que is an innovative broad-spectrum COVID-19 mRNA vaccine designed and developed for the variant strains of the novel coronavirus and encoding a full-length S protein chimera. The clinical trial program has been carried out to cover the currently popular strains. The antigen integrates all mutation sites of the Alpha variant strain and key mutation sites of the Beta variant strain, including 7 mutation sites of the Omicron variant strain. The company
stated that the COVID-19 vaccine based on the mRNA technology route is one of the key technical routes deployed by the Ministry of Science and Technology. It is an innovative technology route product. Currently, no domestic company has a new crown vaccine product with this technology route on the domestic market. There is no complete precedent for relevant trial arrangements and follow-up work.
Source: Read Chuang Finance
Review: Yu Fanghua
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-